2006: A stellar year for financing

Stacy Lawrence

Last year, biotech excelled in terms of financing, but failed to set the stock markets alight. Total biotech financing surpassed 2000 levels to reach \$46 billion, although much of this came from partnership deals

Stock market performance

Mainstream indices closed strongly to finish the year with double-digit increases, whereas biotech indices had no gains or some losses after recovering in the third quarter.



All indices reset to 100 at start of year for better visualization of annual trend. Source: Multex, BioCentury

Global biotech initial public offerings

Markets in Europe continued to account for a significant share of IPO funds raised, with those in Asia-Pacific also contributing.




Notable 2006 biotech deals

			.	
	Company	Amount raised	Percent change in stock price	Date
IPOs	(Lead underwriters)	(\$ millions)	since offer ¹	launched
	Altus Pharmaceuticals	105.0	26%	1/26/06
	(Merrill Lynch., Morgan Stanley,			
	SG Cowen)			
	Renovo (Goldman Sachs)	99.9	101%	7/4/06
	Newron Pharmaceuticals	99.0	-3%	12/8/06
	(Lehman Brothers,			
	Morgan Stanley)			
	Affymax (Morgan Stanley)	92.5	38%	12/14/06
	Wilex (WestLB, Sal.	70.2	1%	11/10/06
	Oppenheim jr. & Cie)			
		Amount		
Venture	Company	invested	Number	
capital	(Lead investors)	(\$ millions)	of round	Date closed
	Kalypsys	100.0	3	11/29/06
	(Tavistock Life Sciences)			
	Macroflux	75.0	1	10/10/06
	(Nomura Phase4 Ventures)			
	Microbia	75.0	5	2/27/06
	(Sigma Capital Management)			
	Xanthus Pharmaceuticals (N/A)	68.0	2	11/30/06
	Merrimack Pharmaceuticals (N/A).	65.0	5	4/3/06
Mergers &		Deal value	Date	
acquisitions	Acquirer/target	(\$ millions)	announced ²	
	Merck/Serono	13,200	9/6/06	
	Abbott Laboratories/Kos	3,700	11/6/06	
	Pharmaceuticals			
	Gilead Sciences/Myogen	3,200	10/6/06	
	Eli Lilly/Icos	2,300	10/6/06	
	Watson Pharmaceuticals/Andrx	1,900	3/6/06	
	AstraZeneca/Cambridge Antibody Technology	1,100	5/6/06	
	Merck/Sirna Therapeutics	1,100	10/6/06	

where payments may (or may not) extend into the future. Debt deals led all categories, almost doubling over 2005, whereas private investment in public equity (PIPEs) increased by more than half.

Global biotech industry financing

Biotech financing increased by ~24% to \$47 billion, with the amount of debt raised almost doubling and PIPEs growing by more than half. Partnering, venture capital and public offerings also grew, albeit more modestly.



Source: BioCentury, Burrill & Company

Global biotech venture capital investment

VC investment climbed by 5% making this the third year in a row of growth.



Source: BioCentury

Lice colla

ensing/		Value	Deal	
aboration			description	Date
	Genmab/GlaxoSmithKline	2,100	Develop of atumumab (anti-CD20 lgG1κ)	12/19/06
	ChemoCentryx/GlaxoSmithKline	1,500	Develop four anti-inflammatory small molecules targeting CCR1/ CCR9/C5aR	8/24/06
	Epix Pharmaceuticals/ GlaxoSmithKline	1,200	Develop small molecules targeting G protein–coupled receptors	12/13/06
	Fibrogen/Astellas	815	License small molecules inhibiting hypoxia-inducible factor prolyl hydroxylase	4/28/06
	Trubion/Wyeth	800	Develop single-chain polypeptides targeting CD20	1/3/06
	Plexxikon/Roche	706	Develop small molecule targeting B-RafV600E gene	10/5/06
	Sirna Therapeutics/	700	Develop RNAi drugs	4/3/06
	GlaxoSmithKline		for respiratory disease	
of Januar	v 3 ² As of deal approximment dat	a Sourca A	RioCentury Recombinan	t Canital

¹As of January 3. ²As of deal announcement date. Source: BioCentury, Recombinant Capital

Stacy Lawrence is a Senior Writer at BioCentury Publications